00918nas a2200361   4500000000100000008004100001260001700042653001500059653001000074653001200084653001600096653001200112653000900124653002000133653003100153653001900184653002100203653001100224653001100235653002000246653001200266653000900278653002500287653002200312100001800334700001800352700001500370245009700385856004100482300001200523490000700535022001400542       1974                            d  c1974 Oct-Dec10aAdolescent10aAdult10aAnimals10aClofazimine10aDapsone10aDogs10aDrug Evaluation10aDrug Resistance, Microbial10aDrug Tolerance10aErythema Nodosum10aFemale10aHumans10aInfant, Newborn10aleprosy10aMale10aMycobacterium leprae10aSkin Pigmentation1 aTolentino J G1 aRodriquez J N1 aAbalos R M00aControlled long-term therapy of leprosy with B663 (lamprene, clofazimine) compared with DDS.  uhttp://ila.ilsl.br/pdfs/v42n4a05.pdf  a416-4180 v42  a0148-916X